Skip to main content

A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance

Completed · Phase 4 · NCT07186595

Conditions: Mid Face Volume Deficit

At a glance

Research payments reported, 2025
$115,491
U.S. investigators named
10
Sites paid
10
Planned or actual enrollment
75

About the trial

Sponsor
AbbVie
Tested
JUVÉDERM VOLUX XC (device), JUVÉDERM VOLUMA XC (device), JUVÉDERM VOLBELLA XC (device), JUVÉDERM VOLLURE XC (device), SKINVIVE by JUVÉDERM (device), JUVÉDERM ULTRA XC (device), JUVÉDERM ULTRA PLUS XC (device)
Dates
Started 2025-09-25; completion 2026-07-08
Results posted
Not yet

The purpose of this study is to evaluate the safety and effectiveness of JUVÉDERM products in adults seeking improvement in facial volume and/or skin quality.

From ClinicalTrials.gov, last updated 2026-08-10. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $115,491 in research payments for this study in 2025 (14 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Pacific Clinical Innovations Inc $20,182
  • Skin Dc PLLC $18,551
  • Skin Research Institute LLC $17,682
  • Kavali Plastic Surgery and Skin Renewal Center $8,551
  • California Institute of Aesthetic Arts Inc $8,551
  • Cosmetic Laser Dermatology $8,421
  • Bellaire Dermatology $8,421
  • Delricht Research at Touro Medical Center $8,421
  • H&h Research LLC $8,421
  • Dermatology Associates of Wisconsin Sc $8,290

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.